XTL Biopharmaceuticals Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization4.96 mln

Float2.46 mln

Earnings Date11/18/2026

Piotroski F-Score

1 / 9

Very weak

Relative Strength

80 / 100

Strongly outperforming

Debt / Equity

0.03

Debt-free

Pre-Tax Margin

-259%

Severely loss-making

ROE

-28.51

Deeply negative

Altman Z-Score

-24.86

Deeply distressed

Business Description

Founded in 1993 and based in Ramat Gan, Israel, XTL Biopharmaceuticals is a drug development company focused on treating autoimmune conditions. Its primary asset, hCDR1, has advanced to Phase II readiness and targets diseases such as lupus and Sjögren's syndrome. The company holds a licensing agreement with Yeda Research and Development to advance hCDR1 across multiple treatment areas.

Key Fundamentals

EPS-0.36

ROE-28.51

ROIC-50.48

ROA-20.40

Interest Cover-241

EBITDA, mln-1.15

EV / EBITDA-8.46

EV / EBIT-8.46

Revenue, mln0.45

EV / Revenue21.50

Quote Details

Last 2.02

Change 0.05 (2.54%)

Open 1.97

Volume 3,682

Turnover 7,437.64

Average Volume 8,418.1

Financial Ratios

Pre-Tax Profit Margin-259

Current Ratio0.61

Price / Book0.99

Debt / Equity0.03

Price / Sales19.78

PEG Ratio2.27

Financial Strength

Altman Z-Score-24.86

Piotroski F-Score 1 / 9

Short Ratio1.13

Short % of Float0.33

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	3.06%	83 / 100
1 Month	-16.18%	22 / 100
2 Months	-31.06%	16 / 100
6 Months	-18.22%	27 / 100
1 Year	-59.92%	14 / 100